This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NW Bio's DCVax Featured On Fox News And Fox Business News





BETHESDA, Md., Nov. 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax ® personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The segment was hosted for Fox by Dr. Marc Siegel, a Clinical Associate Professor at NYU's Langone Medical Center, who describes Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body.

Dr. Lee Tessler, participating in a current late stage Phase III trial of the DCVax immune therapy for brain cancer at the Long Island Brain Tumor Center, describes the process that begins with surgical removal of the patient's tumor. The patient's immune cells are then harvested and exposed in the laboratory to the biomarkers taken from the patient's tumor. These conditioned immune cells are then injected back into the patient through a simple injection under the skin in the upper arm, similar to a flu shot.  The conditioned ("educated") immune cells then mobilize the patient's immune system to now fight any tumor cells bearing the same biomarkers wherever such tumor cells are found in the body. 

According to Dr. Siegel, some patients with Glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, in preliminary trials have seen their survival times more than double from what would be expected under the current standard of care (which consists of surgical removal of the tumor,  radiation and chemotherapy). The final (Phase III) stage of DCVax clinical trials for GBM is being conducted at more than 50 sites across the US, as well as in Europe.

"Each cancer vaccine is personalized, and it takes just eight days to produce enough for three-to-five years' worth of treatment," remarks Dr. Siegel. "It's more cost-effective than older cancer vaccines, and the side effects are minimal versus standard treatments."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs